Metformin Alleviates Endometriosis and Potentiates Endometrial Receptivity via Decreasing VEGF and MMP9 and Increasing Leukemia Inhibitor Factor and HOXA10Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat Was Studied?
This in vivo study tested whether metformin can treat endometriosis and improve endometrial receptivity, and probed the mechanism. The volume of endometriotic implants was measured, along with the protein and mRNA expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9), and of the endometrial-receptivity markers leukemia inhibitor factor (LIF) and HOXA10.
Who Was Studied?
Mature female Wistar albino rats with experimentally induced endometriosis, assigned to a high-dose metformin group (200 mg/kg per day), a low-dose group (100 mg/kg per day), and controls.
What Were the Key Findings?
Metformin significantly suppressed the growth of endometriotic implants and reduced VEGF and MMP-9 (protein and mRNA) in the lesions, while significantly upregulating LIF and HOXA10 in the eutopic endometrium. The anti-growth and pro-receptivity effects were optimal at 100 mg/kg per day.
What Are the Implications?
In this model metformin both alleviated endometriosis (less angiogenesis and tissue remodeling) and improved markers of endometrial receptivity, pointing to a potential dual benefit for disease control and fertility. As an approved drug, metformin is an attractive repurposing candidate, though the findings are preclinical and need clinical confirmation.